Immunological changes in peripheral blood following nasal allergen challenge in subjects with allergic rhinitis pre‐ and post‐peptide immunotherapy: an open‐label clinical study

We investigated immunological changes in peripheral blood samples obtained from individuals with allergic rhinitis (AR), triggered by exposure to cat allergen, who were receiving peptide immunotherapy. Ten cat-sensitized AR individuals received cat peptide antigen desensitization (Cat-PAD, Circassia Pharmaceuticals PLC, Oxford, UK)1 , an experimental peptide immunotherapy for AR; participants were treated with four intradermal injections (at 4-week intervals) of 6 nmol Cat-PAD.